Basis: Latest reported fiscal year. Source: stored company filings and market data; unavailable inputs remain N/A.
The EBITDA margin is N/A as of Tuesday, October 6, 2026.
EBITDA MARGIN
N/A
Market Cap
$10.94M
EBITDA Margin
-284.92%
TTM Avg
-261.31%
3Y Avg
-2315.78%
5Y Avg
-2461.07%
Market Cap
$10.68M
EBITDA Margin
-2404.23%
TTM Avg
-2020.23%
3Y Avg
-5031.76%
5Y Avg
-7490.37%
Market Cap
$11.00M
EBITDA Margin
-1346.05%
TTM Avg
-2835.20%
3Y Avg
-1619.25%
5Y Avg
-1619.25%
Market Cap
$11.02M
EBITDA Margin
-10625.29%
TTM Avg
-6424.40%
3Y Avg
-6424.40%
5Y Avg
-6424.40%
Market Cap
$11.08M
EBITDA Margin
28.31%
TTM Avg
28.31%
3Y Avg
28.31%
5Y Avg
-18969.31%
Market Cap
$11.12M
EBITDA Margin
-5625.93%
TTM Avg
-8506.17%
3Y Avg
-6687.48%
5Y Avg
-5181.84%
| NAME | MARKET CAP | EBITDA MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Polyrizon Ltd. (PLRZ) | $10.83M | N/A | N/A | N/A | N/A |
| BioVie Inc. (BIVI)vs › | $10.86M | N/A | N/A | N/A | N/A |
| Cerenome, Inc. (CNSY)vs › | $10.94M | -284.92% | -261.31% | -2315.78% | -2461.07% |
| Pluri Inc. (PLUR)vs › | $10.68M | -2404.23% | -2020.23% | -5031.76% | -7490.37% |
| CytoMed Therapeutics Limited (GDTC)vs › | $11.00M | -1346.05% | -2835.20% | -1619.25% | -1619.25% |
| Lisata Therapeutics, Inc. (LSTA)vs › | $11.02M | -10625.29% | -6424.40% | -6424.40% | -6424.40% |
| Kiora Pharmaceuticals, Inc. (KPRX)vs › | $11.08M | 28.31% | 28.31% | 28.31% | -18969.31% |
| VistaGen Therapeutics, Inc. (VTGN)vs › | $11.12M | -5625.93% | -8506.17% | -6687.48% | -5181.84% |
| Adial Pharmaceuticals, Inc. (ADIL)vs › | $10.45M | N/A | N/A | N/A | N/A |
| Caring Brands, Inc. (CABR)vs › | $11.36M | -133689.80% | -133689.80% | -133689.80% | -133689.80% |
Gross Margin
N/A
EBITDA Margin
N/A
Operating Margin
N/A
Net Margin
N/A
Formula: EBITDA Margin = (EBITDA / Revenue) × 100
Why EBITDA Margin matters:
EBITDA Margin = EBITDA / Revenue
EBITDA margin measures operating profitability before interest, taxes, depreciation, and amortization as a percentage of revenue.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
